In a stunning setback, FDA spurns Eli Lilly’s marketing application for baricitinib, demands more data
The FDA has rejected Eli Lilly’s blockbuster contender baricitinib, saying that the pharma giant will need to gather significantly more data before regulators will …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.